Effects of tomato extract on platelet function: A double-blinded crossover study in healthy humans

American Journal of Clinical Nutrition

Volumn 84, Issue 3, 2006, Pages 561-569

  O'Kennedy, Niamh ^a,b   Crosbie, Lynn ^a   Whelan, Stuart ^a   Luther, Vanessa ^b   Horgan, Graham ^c   Broom, John I ^d,e   Webb, David J ^f   Duttaroy, Asim K ^g  

^a PROVEXIS PLC   (United Kingdom)

^b ROWETT RESEARCH INSTITUTE   (United Kingdom)

^c BIOMATHEMATICS AND STATISTICS SCOTLAND   (United Kingdom)

^d ROBERT GORDON UNIVERSITY   (United Kingdom)

^e NHS GRAMPIAN   (United Kingdom)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g UNIVERSITY OF OSLO   (Norway)

Author keywords

Cardiovascular disease; Natural antiplatelet agents; Platelet; Thrombosis; Tomato

Indexed keywords

ADENOSINE DIPHOSPHATE; C REACTIVE PROTEIN; COLLAGEN; HOMOCYSTEINE; FIBRINOLYTIC AGENT; PLANT EXTRACT;

ADULT; ARTICLE; DIET SUPPLEMENTATION; DOSE RESPONSE; FEMALE; FOOD INTAKE; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TOMATO; AGED; BLOOD; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR DISEASE; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOSIS; TIME;

LYCOPERSICON ESCULENTUM;

AGED; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LYCOPERSICON ESCULENTUM; MALE; MIDDLE AGED; PLANT EXTRACTS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; THROMBOSIS; TIME FACTORS;

EID: 33750142267     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/84.3.561     Document Type: Article

References (48)

1. Mann K. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999;82:165-74.
2. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-72.
3. Libby P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis and stabilization. Am J Cardiol 2000;86:3J-8J.
4. Ruggeri Z. Mechanisms initiating platelet thrombus formation. Thromb Haemost 1997;78:611-6.
5. Kulkarni S, Dopheide S, Yap C, et al. A revised model of platelet aggregation. J Clin Invest 2000;105:783-91.
6. Dong Z, Chapman S, Brown A, Frenette P, Hynes R, Wagner D. Combined role of P- and E-selectins in atherosclerosis. J Clin Invest 1998;102:145-52.
7. Furman M, Benoit S, Barnard M, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998;31:352-8.
8. Zaman A, Helft G, Worthley S, Badimon J. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 2000;149:251-66.
9. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
10. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists Collaboration. BMJ 2002;324:71-86.
11. Boersma E, Harrington R, Moliterno D, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98.
12. Mehta S, Yusuf S. The Clopidogrel in Unstable Angina-Prevent Recurrent Events (CURE) trial program: rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. The Clopidogrel in Unstable Angina-Prevent Recurrent Events (CURE) Study Investigators. Eur Heart J 2000;21:2033-41.
13. Smith S, Blair S, Bonow R, et al. AHA/ACC scientific statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104:1577-9.
14. Weisman S, Graham D. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002;162:2197-202.
15. Wald N, Law M. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1-6.
16. Law M, Wald N, Morris J, Jordan R. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427-31.
17. Trip M, Cats V, van Capelle F, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990;322:1549-54.
18. White J. Platelets and atherosclerosis. Eur J Clin Invest 1994;24:25-9.
19. Osterud B. A global view on the role of monocytes and platelets in atherogenesis. Thromb Res 1997;85:1-22.
20. Pearson T, Blair S, Daniels S, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronory or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388-91.
21. Sanmuganathan P, Ghahamani P, Jackson P, Wallis E, Ramsay L. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 2001;85:265-71.
22. Eidelman R, Herbert P, Weisman S, Hennekens C. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003;163:2006-10.
23. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002;136:161-72.
24. Dutta-Roy A, Crosbie L, Gordon M. Effects of tomato extract on human platelet aggregation in vitro. Platelets 2001;12:218-27.
25. O'Kennedy N, Crosbie L, van Lieshout M, Broom J, Webb D, Duttaroy A. Effects of antiplatelet activity of tomato extract on platelet function in vitro and ex vivo: a time-course cannulation study. Am J Clin Nutr 2006;84:570-9.
26. Calder A, Garden K, Anderson S, Lobley G. Quantitation of blood and plasma amino acids using isotope dilution electron impact gas chromatography/mass spectrometry with U-(13)C amino acids as internal standards. Rapid Commun Mass Spectrom 1999;13:2080-3.
27. Adult biochemistry and haematology reference ranges for Grampian region. Aberdeen, United Kingdom: Clinical Biochemistry Department, NHS Grampian, 2002.
28. Lazarus S, Garg M. Tomato extract inhibits human platelet aggregation in vitro without increasing basal cAMP levels. Int J Food Sci Nutr 2004;249-56.
29. Yamamoto J, Taka T, Yamada K, et al. Tomatoes have natural antithrombotic effects. Br J Nutr 2003;90:1031-8.
30. Ueland P, Refsum H, Beresford S, Vollset S. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000;72:324-32.
31. Ridker P. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 2003;92:17K-22K.
32. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999;81:165-76.
33. Aukrust P, Waehre T, Damas J, Gullestad L, Solum N. Inflammatory role of platelets in acute coronary syndromes. Heart 2001;86:605-6.
34. Leoncini G, Pascale R, Signorello M. Effects of homocysteine on L-arginine transport and nitric oxide formation in human platelets. Eur J Clin Invest 2003;33:713-9.
35. Signorello M, Pascale R, Leoncini G. Effect of homocysteine on arachidonic acid release in human platelets. Eur J Clin Invest 2002;32:279-84.
36. Dalton M, Gadson PJ, Wrenn R, Rosenquist T. Homocysteine signal cascade: production of phospholipids, activatation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB J 1997;11:708-11.
37. Khajuria A, Houston D. Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis. Blood 2000;96:966-72.
38. Alam S, Nasser S, Fernainy K, Habib A, Badr K. Cytokine imbalance in acute coronary syndrome. Curr Opin Pharmacol 2004;4:166-70.
39. Hu F, Rimm E, Stampfer M, Ascherio A, Spiegelman D, Willet W. Prospective study of major dietary patterns and risk of coronary heart disease in men. Am J Clin Nutr 2000;72:912-21.
40. Hennekens C, Dyken M, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997;96:2751-3.
41. US Food and Drug Administration. Internal analgesic, antipyretic and antirheumatic drug products for over-the-counter human use: proposed amendment to the tentative final monograph. Fed Regist 1996;61:30002.
42. Eikelboom J, Hirsh J, Weitz J, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.
43. Patrono C. Aspirin resistance: definition, mechanisms and clinical readouts. J Thromb Haemost 2003;1:1710-3.
44. Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 1998;79:691-705.
45. McKee S, Sane D, Deliargyris E. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms and clinical significance. Thromb Haemost 2002;88:711-5.
46. Peters J, Shamire R. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina-prevent Recurrent Events (CURE) study. The Clopidogrel in Unstable angina-prevent Recurrent Events (CURE) trial investigators. Circulation 2003;108:1682-7.
47. Steinhubl S, Berger P, Mann JT III, Fry E. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
48. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. US Preventive Services Task Force. Ann Intern Med 2002;136:157-60.